Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
Both non-transfusion-dependent and transfusion dependent cohorts met their respective primary and secondary endpoints
Subscribe To Our Newsletter & Stay Updated
